Investigational drug · Phase 3
Paxlitaxel
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Squamous Non Small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: May 2, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Paxlitaxel"
First trial start
2023
Aug 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Paxlitaxel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Squamous Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Paxlitaxel" as an intervention, largest first.
- AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
AkesoIndustry
NCT05840016 · 532 participants · Start Aug 17, 2023 · Primary completion Feb 28, 2025
Drug: AK112, Carboplatin, Paxlitaxel; Tislelizumab, Carboplatin, Paxlitaxel · For: Advanced Squamous Non Small Cell Lung Cancer
Sites: Shanghai, China
- Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBCNot yet recruiting
Shuangyue LiuAcademic, hospital or other
NCT07103447 · 54 participants (planned) · Start Sep 10, 2025 · Primary completion Dec 31, 2027
Drug: AK112, Carboplatin, Paxlitaxel · For: Breast Cancer - Female
Newest research
PubMed records naming it or its code names, newest first.
- A Therapeutic Side Effect on Hydatid Cyst after Lung Cancer Treatment: A Case Report.
Akyuz C, Çorbaci K · Iran J Parasitol 2026
- Discovery of a novel Genipin derivative targeting YB-1 to enhance the P-glycoprotein-mediated paclitaxel sensitivity of paclitaxel-resistant non-small cell lung cancer.
Deng L, Zhang G, He M, et al. · Eur J Med Chem 2025
- Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.
Lama J, Winograd J, Codelia-Anjum A, et al. · Curr Urol Rep 2024
- Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients.
Robertson J, Raizer J, Hodges JS, et al. · J Peripher Nerv Syst 2018
- Five-year follow-up of the endothelial progenitor cell capturing stent versus the paxlitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis.
Woudstra P, Kalkman DN, Beijk MA, et al. · Catheter Cardiovasc Interv 2018
- Preparation, characterization, and efficacy of thermosensitive liposomes containing paclitaxel.
Wang ZY, Zhang H, Yang Y, et al. · Drug Deliv 2016
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.